ライフサイエンスコーパス: central administration

1 c-Fos expression in GnRH neurons only after central administration.

2 ing hormone (LH) release after peripheral or central administration in Kiss1- or Gpr54 (Kiss1r)-null

3 g hormone (GnRH) release after peripheral or central administration in mice.

4 ervation of an acute orexigenic effect after central administration in mice.

5 hypothalamic signaling molecules, but their central administration induces different effects on hepa

6 vity of relatively short duration whereas on central administration it had only a KOR-antagonist acti

7 In addition, chronic central administration of 1,25D3 dramatically decreased

8 Central administration of 1-10 microg of peptide elicits

9 Central administration of 14 did not produce locomotor e

10 Central administration of 17beta-estradiol (E2) decrease

11 o extend the dissimilar efficacy profiles of central administration of a CRF agonist, r/h CRF(1-41),

12 ic leptin overexpression was induced through central administration of adeno-associated virus-encodin

13 restingly, NPY-/- mice are hypersensitive to central administration of AgRP(83-132), yet exhibit a no

14 Finally, central administration of alphaCGRP to adult hybrid mice

15 sion in the mediobasal hypothalamus and that central administration of an NPY Y(1) receptor antagonis

16 Central administration of analogue 2 in rats increased f

17 rain and peripheral cholinergic systems, and central administration of anticholinergic drugs in depen

18 (1) or delta opioid antagonists, and through central administration of antisense oligodeoxynucleotide

19 Central administration of bicuculline (a GABA(A) recepto

20 MJN110 (which selectively elevates 2-AG) and central administration of both MJN110 and the CB1 antago

21 The central administration of C75, a potent inhibitor of the

22 Central administration of CGRP activates the hypothalamo

23 Central administration of corticotropin-releasing hormon

24 However, the effect of central administration of CRF in these rat strains has y

25 Central administration of CRH results in endocrinologica

26 In contrast, central administration of DHT, 3beta-diol, and the ERbet

27 Central administration of DPDPE (delta-selective agonist

28 neral opioid antagonist, naltrexone, through central administration of either general, mu, mu(1), kap

29 Here, we show that the central administration of estradiol rapidly increases th

30 After central administration of excess Ang II, the reduction o

31 ormones compared with glucose ingestion, and central administration of fructose provokes feeding in r

32 food deprivation are reduced by systemic and central administration of general opioid antagonists.

33 Central administration of GLP-1 augmented glucose-stimul

34 Central administration of GLP-1 increases plasma cortico

35 Central administration of glucagon like peptide-1 (GLP-1

36 Central administration of glucagon-like peptide-1 (GLP-1

37 nts indicate that the anorexigenic effect of central administration of glucose was blunted by coinjec

38 Similar results were observed following central administration of GM-CSF in mice.

39 We demonstrate that central administration of gp120 (4 microg) significantly

40 Central administration of IL-1 (1 or 2 ng/mouse) depress

41 Central administration of IL-1beta (10 ng) also signific

42 Central administration of IL-1beta suppresses natural ki

43 Finally, both peripheral and central administration of IL-1beta, itself, induced sick

44 In addition, in conscious rats, central administration of IMD results in increased plasm

45 Systemic or central administration of leptin alone did not alter GP,

46 Central administration of leptin to peripherally leptin-

47 Central administration of leucine increases hypothalamic

48 Chronic central administration of MCH and adenoviral vectors inc

49 agonist, inhibited food intake stimulated by central administration of MCH, reduced consumption of pa

50 e been observed in antinociception following central administration of morphine into either the later

51 Central administration of MTII for 4 days (10 nmol/day)

52 ression in the brain was analyzed, following central administration of N6-cyclohexyladenosine.

53 Central administration of neuropeptide Y (NPY) potently

54 Central administration of NPS increases locomotor activi

55 Central administration of NPY (10 microg) also enhanced

56 d the metabolic and anorectic effects of the central administration of oleic acid.

57 In normal rats, central administration of orexin or exposure to certain

58 In rodent studies, central administration of orexin peptides increases food

59 Central administration of orexin-A acutely suppressed ca

60 level dependent (BOLD) fMRI to test whether central administration of oxytocin 45-60 min before fMRI

61 Beginning in 1979 with the first report that central administration of oxytocin stimulates maternal b

62 se and alcohol-seeking, we demonstrated that central administration of peptide antagonists for relaxi

63 hey also have a severely blunted response to central administration of peptide YY (PYY).

64 d (b) to further characterize the effects of central administration of QRFP(26) on energy balance in

65 Recognizing that central administration of QRFP26 and QRFP43 increases hi

66 Central administration of recombinant CTRP13 suppressed

67 Central administration of recombinant protein suppressed

68 Finally, central administration of ROS alone increased c-fos and

69 We showed that central administration of senktide (NK3R agonist) induce

70 related cardiovascular responses elicited by central administration of the cannabinoid receptor (CB(1

71 esponse to solicitous males in females after central administration of the D1-like agonist SKF38393 a

72 The central administration of the fatty acid synthase (FAS)

73 Central administration of the long-chain fatty acid olei

74 ing schedule attenuated rats' sensitivity to central administration of the melanocortin agonist MTII.

75 Central administration of the melanocortin receptor agon

76 th this compound in MC4-R knockout mice, and central administration of this compound had no effect on

77 Central administration of WIN 55,212-2 significantly inc

78 knockout (KO) induces alcohol drinking, and central administrations of CRF reduce alcohol intake.

79 Central-administration of oxytocin antagonist attenuated